On 22 June 2026, AbbVie and Apogee Therapeutics announced that they have entered into a definitive agreement for the acquisition by AbbVie of all outstanding shares of Apogee Therapeutics in an all-cash transaction valued at approximately USD$10.9 billion ($135.11 per share).
The transaction is expected to close in Q3/2026, subject to closing conditions including Apogee shareholder approval and receipt of regulatory approvals.
According to the companies, the acquisition of Apogee “holds potential for substantial shareholder value creation with mega-blockbuster peak sales potential across Apogee’s pipeline of assets”.
Apogee’s pipeline of assets includes zumilokibart (APG777) for the treatment of inflammatory diseases, including atopic dermatitis and asthma. Zumilokibart is a subcutaneous antibody that is being positioned as a competitor to Eli Lilly’s Ebglyss® (lebrikizumab) and Regeneron/Sanofi’s Dupixent® (dupilumab). In the Phase II clinical trial, zumilokibart demonstrated strong efficacy and a safety profile consistent with other medicines in its class. Phase III trials are set to commence in 2026, with an anticipated commercial launch in 2029.
The acquisition of Apogee complements AbbVie’s current immunology portfolio, which includes Humira® (adalimumab), Skyrizi® (risankizumab) and Rinvoq® (upadacitinib) and generated $7.29 billion in the first quarter of 2026.